Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Aflibercept in Vitrectomized DME
NCT06662994Phase 4Recruiting
- Sponsor
- Retina Consultants of Orange County
- Start
- Jul 2025
- Primary completion
- Aug 2026
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in diabetic macular edema (DME), sponsored by Retina Consultants of Orange County. Primary endpoint: Visual acuity changes at 12 months. Started Jul 2025; status: recruiting.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06662994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06662994.